Rita C. Peters

Added manufacturing capabilities, partnerships, and regulatory milestones mark recent achievements by API developers.

Industry experts examine reasons why the quality and composition of excipients can vary including environmental factors, processing methods, raw material quality, manufacturing location changes, and operator actions.

Contract service providers are playing a more diverse role in drug development.

The quality and composition of excipients can vary due to environmental factors, processing methods, raw material quality, manufacturing location changes, and even operator actions.

API development and manufacturing companies expanded their capabilities, built partnerships, and achieved milestones in regulatory inspections.

For a bio/pharma industry in flux, contract services are playing a greater-and more diverse-role in drug development.

Pharmaceutical Technology Europe Marks 25 years of drug-development advances.

FDA draft guidances seek to maintain accurate drug information for patients in new media.

Changes are needed to maintain US biopharma innovation leadership.

Changes are needed to maintain US biopharma innovation leadership.

Britain’s Sunday Times has reported that Pfizer approached AstraZeneca with a $101 billion purchase offer.

More media options open publishing opportunities for drug development experts.

ISPE and PDA take on the challenge of recommending quality metrics.

The critically acclaimed television show Breaking Bad told the tales of a high school chemistry teacher who, after a diagnosis of advanced cancer, started a methamphetamine laboratory in order to support his family. While this is not the career path the chemical industry wants to endorse, the popular show did demonstrate applied science in action. At InformEx 2014, Donna Nelson, professor of organic chemistry at the University of Oklahoma and a scientific advisor for the program, will discuss her role in the program.

A survey of BioPharm International readers found that single-use systems and other technologies are driving process efficiencies in biomanufacturing, but there is room for improvement.

While the Affordable Care Act, Pope Francis, and the government shutdown were top general news stories in 2013, the bio/pharmaceutical industry had its own headlines.

Generics, market dynamics, and global demand are changing drug-spending patterns.

Generics, market dynamics, and global demand are changing drug spending patterns.

Pharmaceutical Technology's 2013 Employment Survey reveals some optimism for the industry's future performance, but ongoing concerns about individual job prospects.

Industry mergers, acquisitions and downsizing contribute to uncertainty in job security in the European bio/pharmaceutical market.

The JOBS Act and FDASIA show early signs of accelerating drug development.

US government agencies, including FDA, faced the first shutdown in 17 years when the House of Representatives and Senate failed to reach agreement on a budget.

As the Supreme Court ruled on generic-drug liability, FDA outlined new rules for warning labels.

Pharma and biotech companies, with the rest of the health care industry, must face change.

Ranbaxy's $500 million settlement for producing adulterated drugs and fradulent data provides a cautionary tale for patients, FDA, and drug manufacturers.

Wanted: Article contributions on drug and process development topics.

The FDA approved updated labeling for Purdue Pharma L.P.?s reformulated OxyContin tablets, but also determined that it will not approve generic versions of the original OxyContin.

In recent years, large pharmaceutical companies have launched a variety of initiatives to restock ailing pipelines and boost business performance including mergers and acquisitions, diversifying business portfolios to non-pharmaceutical products, downsizing, spinoffs, and entering the biopharmaceutical arena.

America's biopharmaceutical companies are using biological processes to develop 907 medicines and vaccines targeting more than 100 diseases, according to a new report.

While the number of patent filings at the European Patent Office in 2012 increased by 5.2% over 2011, pharmaceutical-based patents remained flat, and biotechnology patents dropped slightly.